miRNA Biomarkers?: Insights in neurodegenerative diseases
DOI:
https://doi.org/10.32776/revbiomed.v37.i2.1378Keywords:
Neurodegeneratives diseases, Transcriptome, mRNAAbstract
microRNAs play a key role in epigenetic and post-transcriptional mechanisms, developing mechanisms that allow us to understand the transcriptomics of brain function; this is an incentive to elucidate the pathogenesis of neurodegenerative diseases, particularly Alzheimer's and Parkinson's diseases, which have a higher incidence; currently, the characterization of miRNAs in the prodromal phase opens new avenues that allow them to be used as promising biomarkers, given their intricate role in various signaling pathways.
References
1. Kay MA. Ruvkun and Ambros recognized for miRNAs. Mol Ther Nucleic Acids. 2024 Nov 20;35(4):102379. doi: 10.1016/j.omtn.2024.102379. PMID: 39640011; PMCID: PMC11617852.
2. Ma YM, Zhao L. Mechanism and Therapeutic Prospect of miRNAs in Neurodegenerative Diseases.
Behav Neurol. 2023 Nov 23;2023:8537296. doi: 10.1155/2023/8537296. PMID: 38058356; PMCID:
PMC10697780.
3. Alkhazaali-Ali Z, Sahab-Negah S, Boroumand AR, Tavakol-Afshari J. MicroRNA (miRNA) as a biomarker for diagnosis, prognosis, and therapeutics molecules in neurodegenerative disease. Biomed Pharmacother. 2024 Aug;177:116899. doi: 10.1016/j.biopha.2024.116899. Epub 2024 Jun 17. PMID: 38889636.
4. Sun E, Motolani A, Campos L, Lu T. The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics
of Alzheimer's Disease. Int J Mol Sci. 2022 Aug 11;23(16):8972. doi: 10.3390/ijms23168972. PMID: 36012242; PMCID: PMC9408758.
5. Hong H, Wang Y, Menard M, Buckley JA, Zhou L, Volpicelli-Daley L, Standaert DG, Qin H, Benveniste
EN. Suppression of the JAK/STAT pathway inhibits neuroinflammation in the line 61-PFF mouse model of Parkinson's disease. J Neuroinflammation. 2024 Sep 1;21(1):216. doi: 10.1186/s12974-024-03210-8. PMID: 39218899; PMCID: PMC11368013
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Paloma del Consuelo Montoya Zamora
This work is licensed under a Creative Commons Attribution 4.0 International License.
Those authors who have publications with this magazine accept the following terms:
Authors will keep their copyright and guarantee the journal the right of first publication of their work, which will be simultaneously subject to the Creative Commons Recognition License that allows third parties to share the work whenever its author is indicated and his first publication in this magazine. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (eg, deposit it in an institutional telematic file or publish it in a monographic volume) whenever the initial publication in this journal is indicated. Authors are allowed and advised to disseminate their work through the Internet (eg in institutional telematic archives or on their website) after the submission has been accepted and published, which can produce interesting exchanges and increase citations of the published work.
(See The effect of open access)
